Group Attacks Depression Device Approval
Evidence Lacking Showing VNS Is Effective, Says Watchdog
Questioning Approval continued...
Cyberonics, a WebMD sponsor, declined to comment on Public Citizen's
criticism of the approval.
The Senate Finance Committee, which has spent the last year and a half
probing approval and safety practices at the FDA, several months ago launched
an investigation into the FDA's handling of Cyberonics' application for VNS's
The committee's senior Republican and Democrat noted in a joint statement
Friday that they would continue their inquiry. "Both the effectiveness and
the safety of medical devices must be ensured prior to their approval by the
Food and Drug administration," say Sen. Charles E. Grassley (R-Iowa) and
Sen. Max Baucus (D-Mont.).
VNS has been on the U.S. market since 1997 as a treatment for severe
epilepsy. More than 22,000 patients have used the device, according to
FDA Defends Approval
The FDA rejected Public Citizen's complaint that the agency lowered its
standards for approving VNS for depressed patients. FDA regulations require
manufacturers to show "a reasonable assurance of safety" to get devices
cleared, while drugs must be shown to be "safe and effective," says FDA
spokeswoman Julie Zawisza.
"This device was approved for a very small subset of patients who are
very, very sick and have failed all other treatment options and have no other
options," she says.
VNS devices will carry "black box" warnings alerting doctors to use
the device only in patients who have failed to improve after four or more other
types of treatment, Zawisza says.
Richard P. Malone, MD, who served on the expert panel that scrutinized the
VNS data, says he was not convinced that the device met the agency's standard
for a reasonable assurance of safety or efficacy.
"The only controlled study was negative. So benefit is clearly a
problem. The studies did show safety concerns, but I don't think they showed
benefit," says Malone, a professor of psychiatry at Drexel University who
voted against approving VNS.